My After Plan

Manufacturer
OHM LABORATORIES INC | Naari Pharma Private Limited
Effective date
2026-09-17
Label type
HUMAN OTC DRUG LABEL
Version
1
Source
daily-update
Hydrated at
2026-09-22 03:02:26

Label at a glance#

ProductMy After Plan
Active ingredientLEVONORGESTREL
Label structure11 sections

Dosage and administration

take as soon as possible within 72 hours (3 days) after unprotected sex. The sooner you take it the better it will work. if you vomit within 2 hours after taking the medication, call a healthcare professional to find out if you should repeat the dose.

Storage and handling

read the instructions, warnings and enclosed product leaflet before use do not use if carton is open or blister seal is broken or missing store at 20 to 25°C (68 to 77°F)

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Drug Facts

Active ingredient

OTC - ACTIVE INGREDIENT SECTION

Levonorgestrel 1.5 mg

Purpose

OTC - PURPOSE SECTION

Emergency contraceptive

Use

INDICATIONS & USAGE SECTION

for women to reduce chance of pregnancy after unprotected sex (if a contraceptive failed or if you did not use birth control)

Warnings

WARNINGS SECTION

Allergy alert

SPL UNCLASSIFIED SECTION

Do not use if you have ever had an allergic reaction to levonorgestrel

Sexually transmitted diseases (STDs) alert

SPL UNCLASSIFIED SECTION

This product does not protect against HIV/AIDS or other STDs.

Do not use

OTC - DO NOT USE SECTION

  • if you are already pregnant (because it will not work)
  • for regular birth control

OTC - ASK DOCTOR/PHARMACIST SECTION

Ask a doctor or pharmacist before use if you are taking efavirenz (HIV medication) or rifampin (tuberculosis treatment) or medication for seizures (epilepsy). These medications may reduce the effectiveness of levonorgestrel.

OTC - WHEN USING SECTION

When using this product you may have

  • menstrual changes
  • tiredness
  • breast pain
  • nausea
  • headache
  • vomiting
  • lower stomach (abdominal) pain
  • dizziness

OTC - KEEP OUT OF REACH OF CHILDREN SECTION

Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away (1-800-222-1222).

Directions

DOSAGE & ADMINISTRATION SECTION

  • take as soon as possible within 72 hours (3 days) after unprotected sex. The sooner you take it the better it will work.
  • if you vomit within 2 hours after taking the medication, call a healthcare professional to find out if you should repeat the dose.

Other information

STORAGE AND HANDLING SECTION

  • read the instructions, warnings and enclosed product leaflet before use
  • do not use if carton is open or blister seal is broken or missing
  • store at 20 to 25°C (68 to 77°F)

Inactive ingredients

INACTIVE INGREDIENT SECTION


Colloidal Silicon dioxide, corn starch, lactose monohydrate, magnesium stearate, potato starch and talc.

Questions or comments?

OTC - QUESTIONS SECTION


For more information, call 1-800-818-4555 toll free, Monday through Friday.

SPL UNCLASSIFIED SECTION

Distributed by:
Ohm Laboratories Inc.
New Brunswick, NJ 08901

PRINCIPAL DISPLAY PANEL - 1.5 mg Tablet Blister Pack Carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 51660-098-11

My After Plan ®
Levonorgestrel Tablet 1.5 mg
Emergency Contraceptive

Reduces the chance of pregnancy after unprotected sex

Not for regular birth control

  • The sooner you take it, the more effective it will be
  • Take as soon as possible within 72 hours (3 days) after unprotected sex
  • Will not harm an existing pregnancy

1 Tablet Levonorgestrel 1.5 mg

One Tablet. One Step.

My After PlanMy After Plan

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 8 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
51660-09851660-098-11

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 7 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A207660-001LEVONORGESTRELLEVONORGESTREL1.5MGTABLET / ORAL2019-05-02

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 45 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10A207660-001LEVONORGESTREL1.5MGTABLET / ORAL2019-05-02d4dbc9d85df4…
2026-10-15 13:18:302026-09A207660-001LEVONORGESTREL1.5MGTABLET / ORAL2019-05-02c2088c7a36db…
2026-09-14 22:38:342026-08A207660-001LEVONORGESTREL1.5MGTABLET / ORAL2019-05-0284e616aacf4f…
2026-08-18 06:07:402026-07A207660-001LEVONORGESTREL1.5MGTABLET / ORAL2019-05-02caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A207660-001LEVONORGESTREL1.5MGTABLET / ORAL2019-05-02011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A207660-001LEVONORGESTREL1.5MGTABLET / ORAL2019-05-0231067a03dcf5…
2025-08-23 18:47 UTC2025-08A207660-001LEVONORGESTREL1.5MGTABLET / ORAL2019-05-026a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A207660-001LEVONORGESTREL1.5MGTABLET / ORAL2019-05-02fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A207660-001LEVONORGESTREL1.5MGTABLET / ORAL2019-05-02b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A207660-001LEVONORGESTREL1.5MGTABLET / ORAL2019-05-0203ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A207660-001LEVONORGESTREL1.5MGTABLET / ORAL2019-05-022680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A207660-001LEVONORGESTREL1.5MGTABLET / ORAL2019-05-025bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A207660-001LEVONORGESTREL1.5MGTABLET / ORAL2019-05-02d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A207660-001LEVONORGESTREL1.5MGTABLET / ORAL2019-05-02d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A207660-001LEVONORGESTREL1.5MGTABLET / ORAL2019-05-0279d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A207660-001LEVONORGESTREL1.5MGTABLET / ORAL2019-05-02301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A207660-001LEVONORGESTREL1.5MGTABLET / ORAL2019-05-021e350fbaab3a…
2024-05-31 18:47 UTC2024-05A207660-001LEVONORGESTREL1.5MGTABLET / ORAL2019-05-028072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A207660-001LEVONORGESTREL1.5MGTABLET / ORAL2019-05-025c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A207660-001LEVONORGESTREL1.5MGTABLET / ORAL2019-05-025d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A207660-001LEVONORGESTREL1.5MGTABLET / ORAL2019-05-024b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A207660-001LEVONORGESTREL1.5MGTABLET / ORAL2019-05-0274a2ff9319b5…
2022-03-09 01:35 UTC2022-03A207660-001LEVONORGESTREL1.5MGTABLET / ORAL2019-05-02bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A207660-001LEVONORGESTREL1.5MGTABLET / ORAL2019-05-02782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A207660-001LEVONORGESTREL1.5MGTABLET / ORAL2019-05-0287673890dc5c…
2021-03-12 10:30 UTC2021-03A207660-001LEVONORGESTREL1.5MGTABLET / ORAL2019-05-025aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A207660-001LEVONORGESTREL1.5MGTABLET / ORAL2019-05-028869cabd3fbd…
2020-11-12 02:37 UTC2020-11A207660-001LEVONORGESTREL1.5MGTABLET / ORAL2019-05-02c0c555d07b60…
2019-12-14 00:12 UTC2019-12A207660-001LEVONORGESTREL1.5MGTABLET / ORAL2019-05-023f01610625f2…
2019-09-15 20:21 UTC2019-09A207660-001LEVONORGESTREL1.5MGTABLET / ORAL2019-05-02b00525d2431f…
2019-07-19 19:46 UTC2019-07A207660-001LEVONORGESTREL1.5MGTABLET / ORAL2019-05-02ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A207660-001LEVONORGESTREL1.5MGTABLET / ORAL2019-05-026a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A207660-001LEVONORGESTREL1.5MGTABLET / ORAL2019-05-021c564ffb4f44…
2023-12-20 04:57 UTC2023-12A207660-001LEVONORGESTREL1.5MGTABLET / ORAL2019-05-02ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A207660-001LEVONORGESTREL1.5MGTABLET / ORAL2019-05-02a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A207660-001LEVONORGESTREL1.5MGTABLET / ORAL2019-05-029b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A207660-001LEVONORGESTREL1.5MGTABLET / ORAL2019-05-02a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A207660-001LEVONORGESTREL1.5MGTABLET / ORAL2019-05-023f0d92c62455…
2023-05-13 08:27 UTC2023-05A207660-001LEVONORGESTREL1.5MGTABLET / ORAL2019-05-02053a50430f4f…
2023-01-26 05:58 UTC2023-01A207660-001LEVONORGESTREL1.5MGTABLET / ORAL2019-05-023bdfa0b2c4d7…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
My After PlanLEVONORGESTRELOHM LABORATORIES INC5baed3c3-bd9c-8a6c-e063-6294a90a699b2026-09-17WarningsExact identifier
ndc (package): 51660-098-11
ndc (product): 51660-098
ndc11 (package): 51660009811
spl id: 5baed416-d001-7834-e063-6394a90a0966
spl set id: 5baed3c3-bd9c-8a6c-e063-6294a90a699b

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.